313 related articles for article (PubMed ID: 17606668)
1. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
Ashton AK; Longdon MC
Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668
[No Abstract] [Full Text] [Related]
2. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
3. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao MC; Liu CY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
[No Abstract] [Full Text] [Related]
4. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of amine uptake inhibitors in urologic diseases.
Michel MC; Ruhe HG; de Groot AA; Castro R; Oelke M
Curr Drug Saf; 2006 Jan; 1(1):73-85. PubMed ID: 18690917
[TBL] [Abstract][Full Text] [Related]
6. Late-onset galactorrhea and menometrorrhagia with venlafaxine use in a migraine patient.
Berilgen MS
J Clin Psychopharmacol; 2010 Dec; 30(6):753-4. PubMed ID: 21057247
[No Abstract] [Full Text] [Related]
7. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics.
Park P; Caballero J; Omidian H
Ann Pharmacother; 2014 Jan; 48(1):86-92. PubMed ID: 24259607
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine-induced cutaneous adverse reaction.
Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
[No Abstract] [Full Text] [Related]
9. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Stahl SM; Grady MM; Moret C; Briley M
CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
11. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
12. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
13. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
14. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
15. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
16. [Duloxetine (Yentreve) in the general practice test: recommendation by the experts. Effective and tolerable therapy of symptoms in female stress incontinence].
Krankenpfl J; 2005; 43(7-10):189-90. PubMed ID: 16515261
[No Abstract] [Full Text] [Related]
17. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Ravindran LN; Eisfeld BS; Kennedy SH
J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
[No Abstract] [Full Text] [Related]
18. Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.
Nutt D; Allgulander C; Lecrubier Y; Peters T; Wittchen U
J Psychopharmacol; 2008 Jun; 22(4):409-16. PubMed ID: 18635721
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine-associated mania.
Shulman RB; Scheftner WA; Nayudu S
J Clin Psychopharmacol; 2001 Apr; 21(2):239-41. PubMed ID: 11270924
[No Abstract] [Full Text] [Related]
20. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
